Related Experiment Videos
Endothelial function and menopause: effects of raloxifene administration
Nicola Colacurci1, Daniela Manzella, Felice Fornaro
1Department of Gynecology and Obstetrics, Second University of Naples, I-80138 Naples, Italy.
Summary
Raloxifene improves endothelial function in postmenopausal women by enhancing endothelial-dependent vasodilation. This selective estrogen receptor modulator reduces cardiovascular risk factors and improves antioxidant capacity.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Pharmacology
Background:
- Postmenopausal women experience more severe endothelial dysfunction compared to premenopausal women.
- Endothelial dysfunction is a key factor in cardiovascular disease development.
Purpose of the Study:
- To evaluate the beneficial effects of raloxifene on endothelial regulation in postmenopausal women.
- To assess raloxifene's impact on endothelial function markers and vasodilation.
Main Methods:
- A double-blind, randomized placebo-controlled trial involving 60 healthy postmenopausal women.
- Treatment with raloxifene (60 mg/d) or placebo for 4 months.
- Assessment of endothelial function via brachial reactivity and measurement of plasma biomarkers.
Main Results:
- Raloxifene significantly reduced LDL cholesterol, triglycerides, and inflammatory markers (VCAM-1, ICAM-1, E-selectin).
- Treatment increased plasma antioxidant capacity (Trolox equivalent antioxidant capacity).
- Raloxifene improved endothelial-dependent vasodilation but not endothelial-independent vasodilation.
Conclusions:
- Raloxifene positively modulates endothelial-dependent vasodilation in postmenopausal women.
- The benefits are likely linked to a reduction in endothelial damage risk factors.
- Raloxifene shows potential as a therapeutic agent for improving vascular health in this population.